Top ▲

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

CD40

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1874

Nomenclature: CD40

Systematic Nomenclature: TNFRSF5

Family: Immune checkpoint catalytic receptors, Tumour necrosis factor (TNF) receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 277 20q13.12 CD40 CD40 molecule
Mouse 1 289 2 85.38 cM Cd40 CD40 antigen
Rat - - Cd40 CD40 molecule
Previous and Unofficial Names Click here for help
CD40 molecule, TNF receptor superfamily member 5 | TNFRSF5
Database Links Click here for help
Alphafold
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Natural/Endogenous Ligands Click here for help
CD40 ligand {Sp: Human}
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5, TRAF6

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
mitazalimab Peptide Hs Agonist 11.0 pKd 2
pKd 11.0 (Kd 1x10-11 M) [2]
CFZ533 Peptide Primary target of this compound Immunopharmacology Ligand Hs Binding 9.2 pKd 1
pKd 9.2 (Kd 6.9x10-10 M) [1]
Description: Measured using a Biacore assay.
Antibody Comments
Other anti-CD40 mAbs in clinical development include ABBV-323 (ravagalimab; for Crohn's disease) and JNJ-64457107 (vanalimab, ADC-1013; a CD40 agonistic mAb in Phase 1 immuno-oncology trial NCT02829099)
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CD40 ligand {Sp: Human} Peptide Ligand is endogenous in the given species Immunopharmacology Ligand Hs - - -
Immunopharmacology Comments
CD40 is a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed on a variety of immune cells, including macrophages, B cells, and dendritic cells (DCs). CD40 plays a key role in the activation of the immune system. Endogenous ligand is CD154 (CD40L) on TH cells. CD40 is an immunotherapy and immuno-oncology clinical target. Anti-CD40 agonistic monoclonal antibodies that induce activation and proliferation of effector and memory T cells, and enhance the immune response against tumour cells, are in clinical development.
Immuno Process Associations
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 5 GO processes, IEA only
GO:0042100 B cell proliferation NAS
GO:0042113 B cell activation IBA
click arrow to show/hide IEA associations
GO:0019724 B cell mediated immunity IEA
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 5 GO processes, IEA only
GO:0002768 immune response-regulating cell surface receptor signaling pathway IBA
GO:0042100 B cell proliferation NAS
GO:0042113 B cell activation IBA
click arrow to show/hide IEA associations
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 6 GO processes
GO:1902216 positive regulation of interleukin-4-mediated signaling pathway IGI
click arrow to show/hide IEA associations
GO:0032735 positive regulation of interleukin-12 production IEA
GO:0034341 response to type II interferon IEA
GO:0036018 cellular response to erythropoietin IEA
GO:0071347 cellular response to interleukin-1 IEA
GO:0071356 cellular response to tumor necrosis factor IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 3 GO processes, IEA only
GO:0002768 immune response-regulating cell surface receptor signaling pathway IBA
click arrow to show/hide IEA associations
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  Inflammation
GO Annotations:  Associated to 3 GO processes
GO:0006954 inflammatory response TAS
click arrow to show/hide IEA associations
GO:0034341 response to type II interferon IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 2 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0019724 B cell mediated immunity IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA

References

Show »

1. Heusser C, Rush J, Vincent K. (2012) Silent fc variants of anti-cd40 antibodies. Patent number: WO2012065950. Assignee: Novartis Ag. Priority date: 15/11/2010. Publication date: 24/05/2012.

2. Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P. (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res, 21 (5): 1115-26. [PMID:25316820]

How to cite this page